Difference between revisions of "Bleomycin (Blenoxane)"
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Aggressive Non-Hodgkin lymphoma]] | ||
*[[Basal cell and squamous cell skin cancer]] | *[[Basal cell and squamous cell skin cancer]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
*[[Unknown primary | Cancer of Unknown Primary]] | *[[Unknown primary | Cancer of Unknown Primary]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| − | *[[ | + | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] |
| + | *[[Penile cancer]] | ||
| + | *[[Sarcoma]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
Revision as of 17:00, 20 June 2013
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Basal cell and squamous cell skin cancer
- Bone cancer
- Cancer of Unknown Primary
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Penile cancer
- Sarcoma
- Testicular cancer
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[2]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[3]